Clinical relevance of apoptotic regulatory proteins in colorectal cancers

Howard C. Masuoka, Frank A. Sinicrope

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Dysregulation of apoptosis or programmed cell death is a hallmark of human cancers that contributes to tumor development and progression, and may confer treatment resistance and therapeutic failure. Apoptosis is governed by both a mitochondria-mediated and a death receptor (DR)-mediated pathway. Within human cancer cells, both apoptotic pathways are regulated by proapoptotic and prosurvival Bcl-2 family proteins. Loss of proapoptotic genes or, alternatively, upregulation of prosurvival genes may lead to tumorigenesis in preclinical models. Expression of Bcl-2 family proteins has been shown to provide prognostic information in certain malignancies, including colon cancers, and therefore may be useful in determining which patients are more likely to suffer recurrence and metastasis. Such markers may assist in selecting patients to receive adjuvant chemotherapy and represent potential targets for therapeutic intervention. In the therapeutic arena, small molecule Bcl-2/Bcl-x L antagonists and DR agonists have been developed that enhance chemosensitivity in preclinical models and currently are undergoing evaluation in cancer patients. This review focuses on the current status of apoptotic regulatory proteins as biomarkers in colorectal cancers and their potential clinical utility.

Original languageEnglish (US)
Pages (from-to)111-117
Number of pages7
JournalCurrent Colorectal Cancer Reports
Volume6
Issue number3
DOIs
StatePublished - Jul 1 2010

Fingerprint

Colorectal Neoplasms
Death Domain Receptors
Neoplasms
Proteins
Apoptosis
Therapeutics
Adjuvant Chemotherapy
Colonic Neoplasms
Genes
Mitochondria
Carcinogenesis
Cell Death
Up-Regulation
Biomarkers
Neoplasm Metastasis
Recurrence

Keywords

  • 5-Flurouracil (5-FU)
  • ABT-737
  • Apoptosis
  • BH3-only protein
  • Bcl-2 (B-cell lymphoma 2)
  • Colorectal cancer (CRC)
  • Death receptor
  • Drug resistance
  • IAP
  • Prognosis
  • Survivin
  • TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)
  • miR (microRNA)

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Cite this

Clinical relevance of apoptotic regulatory proteins in colorectal cancers. / Masuoka, Howard C.; Sinicrope, Frank A.

In: Current Colorectal Cancer Reports, Vol. 6, No. 3, 01.07.2010, p. 111-117.

Research output: Contribution to journalReview article

@article{f93dacbd243c4b8197c2399ea5747a54,
title = "Clinical relevance of apoptotic regulatory proteins in colorectal cancers",
abstract = "Dysregulation of apoptosis or programmed cell death is a hallmark of human cancers that contributes to tumor development and progression, and may confer treatment resistance and therapeutic failure. Apoptosis is governed by both a mitochondria-mediated and a death receptor (DR)-mediated pathway. Within human cancer cells, both apoptotic pathways are regulated by proapoptotic and prosurvival Bcl-2 family proteins. Loss of proapoptotic genes or, alternatively, upregulation of prosurvival genes may lead to tumorigenesis in preclinical models. Expression of Bcl-2 family proteins has been shown to provide prognostic information in certain malignancies, including colon cancers, and therefore may be useful in determining which patients are more likely to suffer recurrence and metastasis. Such markers may assist in selecting patients to receive adjuvant chemotherapy and represent potential targets for therapeutic intervention. In the therapeutic arena, small molecule Bcl-2/Bcl-x L antagonists and DR agonists have been developed that enhance chemosensitivity in preclinical models and currently are undergoing evaluation in cancer patients. This review focuses on the current status of apoptotic regulatory proteins as biomarkers in colorectal cancers and their potential clinical utility.",
keywords = "5-Flurouracil (5-FU), ABT-737, Apoptosis, BH3-only protein, Bcl-2 (B-cell lymphoma 2), Colorectal cancer (CRC), Death receptor, Drug resistance, IAP, Prognosis, Survivin, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), miR (microRNA)",
author = "Masuoka, {Howard C.} and Sinicrope, {Frank A.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1007/s11888-010-0051-4",
language = "English (US)",
volume = "6",
pages = "111--117",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Clinical relevance of apoptotic regulatory proteins in colorectal cancers

AU - Masuoka, Howard C.

AU - Sinicrope, Frank A.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Dysregulation of apoptosis or programmed cell death is a hallmark of human cancers that contributes to tumor development and progression, and may confer treatment resistance and therapeutic failure. Apoptosis is governed by both a mitochondria-mediated and a death receptor (DR)-mediated pathway. Within human cancer cells, both apoptotic pathways are regulated by proapoptotic and prosurvival Bcl-2 family proteins. Loss of proapoptotic genes or, alternatively, upregulation of prosurvival genes may lead to tumorigenesis in preclinical models. Expression of Bcl-2 family proteins has been shown to provide prognostic information in certain malignancies, including colon cancers, and therefore may be useful in determining which patients are more likely to suffer recurrence and metastasis. Such markers may assist in selecting patients to receive adjuvant chemotherapy and represent potential targets for therapeutic intervention. In the therapeutic arena, small molecule Bcl-2/Bcl-x L antagonists and DR agonists have been developed that enhance chemosensitivity in preclinical models and currently are undergoing evaluation in cancer patients. This review focuses on the current status of apoptotic regulatory proteins as biomarkers in colorectal cancers and their potential clinical utility.

AB - Dysregulation of apoptosis or programmed cell death is a hallmark of human cancers that contributes to tumor development and progression, and may confer treatment resistance and therapeutic failure. Apoptosis is governed by both a mitochondria-mediated and a death receptor (DR)-mediated pathway. Within human cancer cells, both apoptotic pathways are regulated by proapoptotic and prosurvival Bcl-2 family proteins. Loss of proapoptotic genes or, alternatively, upregulation of prosurvival genes may lead to tumorigenesis in preclinical models. Expression of Bcl-2 family proteins has been shown to provide prognostic information in certain malignancies, including colon cancers, and therefore may be useful in determining which patients are more likely to suffer recurrence and metastasis. Such markers may assist in selecting patients to receive adjuvant chemotherapy and represent potential targets for therapeutic intervention. In the therapeutic arena, small molecule Bcl-2/Bcl-x L antagonists and DR agonists have been developed that enhance chemosensitivity in preclinical models and currently are undergoing evaluation in cancer patients. This review focuses on the current status of apoptotic regulatory proteins as biomarkers in colorectal cancers and their potential clinical utility.

KW - 5-Flurouracil (5-FU)

KW - ABT-737

KW - Apoptosis

KW - BH3-only protein

KW - Bcl-2 (B-cell lymphoma 2)

KW - Colorectal cancer (CRC)

KW - Death receptor

KW - Drug resistance

KW - IAP

KW - Prognosis

KW - Survivin

KW - TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)

KW - miR (microRNA)

UR - http://www.scopus.com/inward/record.url?scp=79952739674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952739674&partnerID=8YFLogxK

U2 - 10.1007/s11888-010-0051-4

DO - 10.1007/s11888-010-0051-4

M3 - Review article

AN - SCOPUS:79952739674

VL - 6

SP - 111

EP - 117

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -